Substance-related disorder

Global Success, Local Roots: Parissa Celebrates 40 Years as The Worldwide Leader in Natural Hair Removal

Retrieved on: 
Tuesday, February 7, 2023
Whole Foods Market, Social responsibility, Substance-related disorder, Hair, Woman, Skin, Walmart, Interview, Family, Loblaws, Ulta Beauty, Shoppers Drug Mart

After immigrating to Vancouver from native country Iran, Moayeri noticed a gap in the market for chemical-free hair removal solutions.

Key Points: 
  • After immigrating to Vancouver from native country Iran, Moayeri noticed a gap in the market for chemical-free hair removal solutions.
  • That's when Moayeri started formulating Canada's first all-natural hair removal product from the comfort of the kitchen.
  • At every touchpoint, Parissa is dedicated to promoting the highest quality hair removal experience with the lowest environmental impact.
  • As Parissa marks its 40-year anniversary as a worldwide leader in natural home hair removal, the company remains firmly rooted in its local and family values as well as its commitment to social responsibility and environmental sustainability.

Field Trip Health & Wellness Announces Posting on the OTC Market

Retrieved on: 
Friday, February 3, 2023
Ketamine, Wellness, Telehealth, TSX Venture Exchange, COVID-19, Substance-related disorder, Government, PHE, Financial Regulatory Authority, OTCQB, Public health emergency, Field trip, Medicine, Public health, Pharmaceutical industry

TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), global leader in the delivery of psychedelic therapies, is pleased to announce that the Company has received approval from the Financial Regulatory Authority (“FINRA”) for its shares to commence trading on the OTCQB Market (“the OTCQB”) in the United States under the symbol “FTHWF” effective February 2, 2023.

Key Points: 
  • TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), global leader in the delivery of psychedelic therapies, is pleased to announce that the Company has received approval from the Financial Regulatory Authority (“FINRA”) for its shares to commence trading on the OTCQB Market (“the OTCQB”) in the United States under the symbol “FTHWF” effective February 2, 2023.
  • Field Trip will continue to trade on the TSX Venture Exchange under its existing symbol “FTHW”.
  • Ronan Levy, Chairman and Chief Executive Officer of Field Trip Health & Wellness, stated, “Being posted on the OTCQB is a key milestone in our evolution as one of today’s leading providers of psychedelic therapy.
  • The Freedom by Field Trip program relies on an exception to the Ryan Haight Act that permitted prescribing of controlled substances such as ketamine by telemedicine during the PHE.

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

Retrieved on: 
Thursday, January 26, 2023
Manuscript, American College, Medical College of Wisconsin, PTSD, Federation of European Neuroscience Societies, Neuropathic pain, IND, COVID-19, Substance-related disorder, Biological Psychiatry (journal), Carleton University, Society, Therapy, Medical college, Inhalation, Conference, LSD, Depression, University, Patient, University of California, San Diego, Patent, Partnership, Canadian Association of College and University Student Services, CSE, Anxiety, GMP, FDA, PCT, Coro de la Pontificia Universidad Católica de Puerto Rico, Data analysis, HPV, Wainwright Securities Inc. v. Wall Street Transcript Corp., FENS, Annual conferences, Alpha-2B adrenergic receptor, Research, Toxicology, Pharmaceutical industry, Vaccine, Medical device, Neuroscience

“We are very excited to be working with Bloom Burton, Canada’s leading healthcare investment banking firm,” said Ahmad Doroudian, CEO of BetterLife.

Key Points: 
  • “We are very excited to be working with Bloom Burton, Canada’s leading healthcare investment banking firm,” said Ahmad Doroudian, CEO of BetterLife.
  • Development of scaled-up (kg batch size) manufacturing of BetterLife’s proprietary form of 2-bromo-LSD (“BETR-001”) using BetterLife’s proprietary synthetic pathway.
  • The starting material and whole synthetic pathway do not involve any controlled substance and, therefore, are not bound by controlled substance regulations.
  • Scientific presentations on BETR-001 preclinical data were made at the following conferences:
    Canadian Association for Neuroscience (CAN) / May 12-15, 2022 / Toronto, Canada.

Global Biostimulants Market Report 2023: Expansion in Organic Agriculture Land and Increase in Crop Production Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Environmental Health, Technology, Other Natural Resources, Agriculture, Natural Resources, Other Manufacturing, Climate Change, Chemicals, Plastics, Food, Beverage, Manufacturing, Sustainability, Retail, Food Tech, Environment, Environmental Policy, Organic Food, Environmental Issues, Water pollution, Substance-related disorder, Pesticide, Soil, Liquid, Disturbance, Amino acid, Erosion, BASF SE, COVID-19, Biodiversity, FMC Corporation, Biodiversity loss, S.P. Bansal, European Environment Agency, SE, Leaf, BASF, UPL, Region, Haifa Group, Organic, USD, GDP, Plant, Biostimulation, Form, European

The global biostimulants market is estimated to be valued at USD 3.5 billion in 2022.

Key Points: 
  • The global biostimulants market is estimated to be valued at USD 3.5 billion in 2022.
  • Organic farming is widely considered a far more sustainable alternative when it comes to food production.
  • The lack of pesticides and a wider variety of plants enhances biodiversity, improves soil quality, and reduces fertilizer or pesticide run-off pollution.
  • The steady growth of the production of fruits & vegetables is expected to strengthen the demand for biostimulants.

Department of Justice Intervenes in Baron & Budd Whistleblower Lawsuit Against Rite Aid

Retrieved on: 
Friday, January 13, 2023
Legal, Professional Services, Substance-related disorder, Pharmacist, U.S. Department of Justice Office of Legislative Affairs, False Claims Act, Office of Inspector General, U.S. Department of Health and Human Services, Hello English (government program), Public health, Government, Safety, Environment, Controlled Substances Act, Justice, Baron & Budd, P.C., Rite Aid, Professional practice of behavior analysis, Medicare, Pharmacy, Tricare, Prescription, Courage, Pharmaceutical industry, Health insurance, Medicaid

Today, the nationally recognized law firm of Baron & Budd announced the U.S. Department of Justice has decided to intervene and take primary responsibility litigating a whistleblower lawsuit filed against Rite Aid for violations of the False Claims Act and the Controlled Substances Act.

Key Points: 
  • Today, the nationally recognized law firm of Baron & Budd announced the U.S. Department of Justice has decided to intervene and take primary responsibility litigating a whistleblower lawsuit filed against Rite Aid for violations of the False Claims Act and the Controlled Substances Act.
  • The whistleblowers in this case are former Rite Aid pharmacy employees represented by Baron & Budd.
  • The suit alleges that Rite Aid consistently disregarded its duties to provide adequate staffing, resources, and information to its pharmacists and did not properly identify, investigate, and resolve red flag prescriptions before dispensing.
  • Instead, the suit alleges that Rite Aid routinely chose profits over people, and created an environment where pharmacists were expected to dispense any and all prescriptions to fuel Rite Aid’s business interests.

Graphene-enhanced Composites Global Market Report 2022: Low Cost Compared to Metal Drives Demand - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Technology, Mobile, Wireless, Semiconductor, Chemicals, Plastics, Other Technology, Telecommunications, Manufacturing, Hardware, Consumer Electronics, Computer, Composite, Substance-related disorder, Metal, Light, Application, USD, Ceramic, Data structure, Polymer, Competition, Research, Carbon fibers

Global Graphene-enhanced Composites Market is projected to grow at an impressive rate through 2028 due to the increase in expenditure on research and development of the graphene enhanced composites.

Key Points: 
  • Global Graphene-enhanced Composites Market is projected to grow at an impressive rate through 2028 due to the increase in expenditure on research and development of the graphene enhanced composites.
  • The main factor influencing the development of composites enhanced by graphene is graphene.
  • The development of composite materials with graphene enhancement has benefited from the technological development for the mass manufacture of graphene.
  • Among the graphene-enhanced composites frequently employed in various end-user applications are those made of polymer, metal, and ceramic materials.

$715+ Billion Worldwide Industrial Tubes Industry to 2031 - Rise in the Oil and Gas Industry is Expected to Propel Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Benchmark, Titanium, Transport, Power, Epichlorohydrin, Zirconium, ECH, Hydrocarbon, Natural gas, Create, Pressure, India Brand Equity Foundation, Sewage, Urea, Carbon, Organization, Vital statistics (government records), Substance-related disorder, Growth, Engineering, Steel, Vacuum, Coronavirus, Biofuel, Marketing, Video game, Oil

The main types of industrial tubs are process pipes, mechanical tubes, heat exchanger tubes, structural tubes, and hydraulic and instrumentation tubes.

Key Points: 
  • The main types of industrial tubs are process pipes, mechanical tubes, heat exchanger tubes, structural tubes, and hydraulic and instrumentation tubes.
  • The rise in the oil and gas industry is expected to propel the growth of the industrial tubes market going forward.
  • The industrial tubes are designed to transport crude and refined petroleum, as well as fuels such as oil, natural gas, and biofuels, efficiently.
  • Therefore, the rise in the oil and gas industry is driving the demand for the industrial tube market.

Galaxy Treats Launches Line of Psychadelic Amanita Mushroom Gummies

Retrieved on: 
Thursday, January 12, 2023
Substance-related disorder, Overalls, Ibotenic acid, Amanita, GABA, Muscimol, Gummy candy, Psilocybin, Relaxation, Telephone, Delta, Growth, Serotonin, Amanita muscaria, Sale, Hallucination, Muscarine, Legal status of psychoactive Amanita mushrooms, Mushroom

Amanita mushrooms (Amanita Muscaria) are easily recognizable, featuring soft, white bodies and stunning red caps with white spots.

Key Points: 
  • Amanita mushrooms (Amanita Muscaria) are easily recognizable, featuring soft, white bodies and stunning red caps with white spots.
  • Packed with 350mg of amanita mushroom extract in each gummy, Galaxy Treats Amanita Mushroom Gummies offer a mildly psychedelic experience that has been referred to as "chill" and "relaxing."
  • Currently, amanita mushroom gummies and other products containing amanita extracts are mostly legal.
  • Galaxy Treats is an industry-leading rare cannabinoid brand offering a premium selection of hemp-derived products including Delta-8 Gummies, Delta 9 Gummies, HHC Gummies, THC-O Gummies, THC-O/HHC Disposables, and now, legal psychedelic mushroom gummies.

Shatterproof Applauds the Passage of the MATE Act to Expand Addiction Education

Retrieved on: 
Friday, December 23, 2022
Public Policy, Government, White House, Federal Government, Public Policy, General Health, Health, Mental Health, Healthcare Reform, Congressional News, Views, Well, Education, Doctor of Nursing Practice, Addiction, Mental health, Legislation, School, Pain, SUD, Substance-related disorder, American College, Health, Voices, Omnibus Appropriations Act, 2009, SMART Recovery, House, Drug Safety, Organization, Buprenorphine, National Council, Drug Enforcement Administration, Federation, National Safety Council, American Society of Addiction Medicine, Drug, Opioid use disorder, Research, MAT, Patient, Representative, Curriculum, Society, Oxford, OUD, Maintenance, Student, American College of Medical Toxicology, MATE, Congress, Suds, Louisiana House of Representatives, University, Addiction medicine, DEA, Speech disorder, Pharmaceutical industry, Medicine, The 39 Clues

Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.

Key Points: 
  • Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.
  • Passage of the MAT Act along with the MATE Act will enable better access to life-saving treatment.
  • The MATE Act mainstreams addiction medical education on SUDs across the nation’s medical educational programs.
  • Shatterproof worked closely with the American Society of Addiction Medicine on the passing of the MATE Act.

Turntide Leverages Ansys to Reduce Development Costs for Electric-Powered Construction Vehicles

Retrieved on: 
Thursday, January 5, 2023
Sand, CES, Vibration, Carbon, Weather, Safety, Substance-related disorder, Shock, Rail transport, 3D printing, Ansys, TurnTide

PITTSBURGH, Jan. 5, 2023 /PRNewswire/ -- Turntide Technologies (Turntide), developer of electrification and sustainable operations technologies, is leveraging Ansys (NASDAQ: ANSS) solutions to produce electric vehicle powertrain components that help its customers transform commercial and industrial vehicles from gas and diesel engines to clean, quiet battery electric machines — a significant step towards achieving global net-zero goals.

Key Points: 
  • While many automakers electrify passenger vehicles, Turntide is focused on supplying electrification solutions for commercial and industrial vehicles, such as construction equipment, agricultural machines, trains, marine and freight movers.
  • These vehicles present greater sustainability challenges than passenger vehicles because of their heavy-duty loads, work cycles, and vibration.
  • Turntide uses a suite of Ansys tools to design and test components for construction equipment such as front wheel loaders or mini excavators.
  • We estimate that we save about 25% on development costs by using simulation."